

# Optimizing Patient Outcomes: Collaborative Perspectives in Oncology



## **Keep pace with rapid advances in cancer treatment.**

Stay informed about the latest evidence-based updates on cancer therapies, safety, and side effect management – empowering interprofessional teams to deliver exceptional care.

### LIVE WEBINAR



**Friday, October 16, 2026**  
**10:00 – 11:00 AM EDT**

### REGISTER

<https://education.nccn.org/node/98730>

### AVAILABLE CREDIT

1.0 AAPA Category 1 CME credit  
1.0 ACPE contact hour  
1.0 AMA PRA Category 1 Credit™  
1.0 ANCC contact hour  
1.0 ANCC pharmacology contact hour  
1.0 Participation


### OVERVIEW

Managing BsAb toxicity requires an interprofessional approach including advanced practitioners, clinical pharmacy specialists, and access to medical specialists in relevant disciplines. Understanding the potential toxicities is crucial for safe and effective use. All the members of the health care team should receive proper education and training regarding BsAb toxicity to understand how to maximize the therapeutic benefits and minimize the potential risks. Optimizing patient outcomes requires care coordination and communication as well as an institution-specific standard operating procedure to prevent morbidity and mortality from BsAbs.

### TARGET AUDIENCE

This program is designed to meet the educational needs of physicians, nurses, nurse practitioners, pharmacists, physician associates and other health care professionals who treat patients with cancer.

## Management of Bispecific T-Cell Engager Toxicities: How to Balance Increased Efficacy with Notable Toxicity



**Oxana Megherea**  
**PharmD, BCOP**  
*Abramson Cancer Center  
at the University of Pennsylvania*



**Patricia Mangan**  
**MSN, RN, APRN-BC, CRNP**  
*Abramson Cancer Center  
at the University of Pennsylvania*

### LEARNING OBJECTIVES

- Outline implementation of an interprofessional standard operating procedure for evaluating product-specific site of care administration and managing bispecific antibody toxicity in clinic and at home.
- Choose appropriate infection prophylaxis strategies for patients with BsAbs.
- Outline a comprehensive therapeutic plan for patient education on signs and symptoms for CRS and ICANS, including recognizing early signs of toxicities and when to seek medical attention.